Please login to the form below

Not currently logged in
Email:
Password:

Immutep

This page shows the latest Immutep news and features for those working in and with pharma, biotech and healthcare.

Immutep slumps on latest efti data in breast cancer

Immutep slumps on latest efti data in breast cancer

Analyst Dr Chris Redhead at Goetzpartners said the outcomes was a “substantial setback” for Immutep, but doesn’t mean that efti is dead. ... Immutep will need to keep its foot on the gas if it hopes to keep pace with some larger, deep-pocketed

Latest news

  • Immutep spikes on trial of its LAG-3 drug with Keytruda Immutep spikes on trial of its LAG-3 drug with Keytruda

    Impressive mid-stage results in NSCLC and HNSCC. Shares in Australian biotech Immutep rose quickly on data for its cancer immunotherapy drug eftilagimod alpha alongside Merck &Co’s Keytruda in solid ... Immutep also has a phase 2b trial of efti ongoing

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics